Background/aims As a module of a standard ultrasound imaging device, acoustic radiation force impulse (ARFI) is a new technology for liver stiffness evaluation (LSE). We aimed to evaluate accuracy, feasibility, reproducibility, and training effect of ARFI for liver fibrosis evaluation.
Background/aims As a module of a standard ultrasound imaging device, acoustic radiation force impulse (ARFI) is a new technology for liver stiffness evaluation (LSE). We aimed to evaluate accuracy, feasibility, reproducibility, and training effect of ARFI for liver fibrosis evaluation.
Methods One hundred and one patients with chronic liver disease had LSE by Fibroscan and ARFI. LSE by ARFI was performed in the two liver lobes by two operators: an expert and a novice. Correlation and agreement were evaluated by the Pearson (Rp) and intraclass (Ric) correlation coefficients. The independent reference for liver fibrosis was fibrosis blood tests.
Results ARFI results, ranging from 0.7 to 4.6 m/s, were well correlated with Fibroscan results (Rp = 0.76). Fibroscan had a significantly higher area under the receiver operating characteristic curve (AUROC) than ARFI for the perprotocol diagnosis of significant fibrosis: 0.890 ± 0.034 versus 0.795 ± 0.047 (P = 0.04). However, LSE failure occurred in zero patients using ARFI versus six patients using Fibroscan (P = 0.03). Thus, on an intention-to-diagnose basis, Fibroscan and ARFI AUROCs for the diagnosis of significant fibrosis were not different: 0.791 ± 0.049 versus 0.793 ± 0.046 (P = 0.98). Interobserver agreement was very good (Ric = 0.84) and excellent for ARFI interquartile range (IQR) r 0.30 (Ric = 0.91). Indeed, agreement was independently predicted only by ARFI IQR, but not by LSE result as earlier observed for Fibroscan. ARFI AUROC was 0.876 ± 0.057 in patients with ARFI IQR ratio r 0.30, and Fibroscan AUROC was 0.912 ± 0.034 in patients with Fibroscan IQR ratio less than 0.21 (P = 0.59). Intersite ARFI agreement between the two liver lobes was fair (Ric = 0.60).
There was no training effect for LSE by ARFI.
Conclusion ARFI is highly feasible and reproducible, and provides diagnostic accuracy similar to Fibroscan. This new device seems noteworthy for the widespread noninvasive diagnosis of liver fibrosis. Eur J Gastroenterol 
Introduction
Liver fibrosis evaluation in chronic liver diseases is a real challenge for physicians. Histological evaluation of a liver biopsy using semiquantitative fibrosis scores has long been considered the gold standard. However, a heterogeneous repartition of fibrosis in the liver induces sampling bias [1] , and the reproducibility of semiquantitative scores of fibrosis is questionable [2] . Furthermore, liver biopsy is an invasive procedure with potentially severe complications [3] , including death, and is thus unsuitable in a screening attitude.
Fibroscan was recently developed by Echosens (Paris, France). This device permits liver stiffness evaluation (LSE) by ultrasonographic elastography. A probe applied on the skin generates a mechanical shear wave and measures its velocity through the liver using ultrasound (Fig. 1a) ; the faster the shear wave, the harder the tissue is [4] . LSE by Fibroscan is noninvasive, takes only a few minutes, requires no training [5] , and produces an immediate result. Several studies have shown that the liver stiffness measured by Fibroscan is well correlated with fibrosis stages, thus leading to an increasing interest for LSE in chronic liver diseases [4] . Recently, two meta-analyses have shown Fibroscan to be highly accurate for the noninvasive diagnosis of cirrhosis [6, 7] . However, LSE by Fibroscan has several limitations: failure of LSE occured in 2-10% of patients [4] mainly because of high-body mass index (BMI) [8] , diagnostic accuracy for significant fibrosis remains insufficient [6, 7] , and reproducibility of LSE results is only fair for low liver stiffness values [9] . Finally, Fibroscan is a costly device and thus not available in all hepatology centers.
More recently, LSE by MRI elastography has been shown to provide high accuracy for the noninvasive diagnosis of liver fibrosis [10, 11] . However, when commercially available, MRI elastography will probably be even more costly, and thus less accessible, than Fibroscan.
In the form of an add-on module for a standard ultrasound imaging device, acoustic radiation force impulse (ARFI) is a new technology for LSE [12] . We evaluated the feasibility, accuracy, reproducibility, and training effect of ARFI in liver fibrosis evaluation.
Patients and methods

Patients
From December 2008 to February 2009, we prospectively enrolled 101 outpatients with chronic liver disease consulting at the Hepato-Gastroenterology Department of the University Hospital of Angers (France). Patients with hepatocellular carcinoma or clinical ascites were not included. Fibroscan and fibrosis blood tests were performed the same day and ARFI within the same week. All patients gave informed consent before being included in the study. The study protocol conformed to the ethical guidelines of the current Declaration of Helsinki.
Liver stiffness evaluation by acoustic radiation force impulse Acoustic radiation force impulse technology ARFI (Acuson S2000 Virtual Touch Tissue Quantification, Siemens, Erlangen, Germany) is a module of a standard ultrasound imaging device. ARFI uses brief and high energy ultrasound pulses producing mechanical excitation along the acoustic wave propagation path [12] . These radiation force excitations generate shear waves directly in the tissue of interest (Fig. 1b) . Conventional pulse-echo ultrasound is used to assess the speed of propagation of the shear wave in a region of interest corresponding to a cylinder, 0.5 cm wide and 1 cm long. The speed of the shear wave, expressed as m/s, increases with the liver parenchyma stiffness [13] . Thus, this method provides a measurement of tissue elasticity or stiffness of liver parenchyma. Both the high-energy pulse and conventional pulse of ultrasounds are produced through the same conventional abdominal probe. In practice, the probe is covered with coupling gel and then applied to the skin. On the conventional two-dimensional B-mode images, the cylindrical region of interest where the liver stiffness is measured is visualized as a 0.5 Â 1 cm green rectangle (Fig. 1c) . This zone can be freely placed on the slices with a depth limitation of 5.5 cm below the skin surface. Owing to probe temperature elevation caused by the high energy pulse, a 2 s interval is required between two measurements.
Operators
LSE by ARFI was performed by two operators: a physician specialized in abdominal radiology with more than 50 LSEs by ARFI performed before the study (expert), and a fellow in radiology with no LSEs performed before the study (novice). The two operators were blinded for the clinical and blood characteristics of the patients and their Fibroscan results. The expert provided a single LSE training session to the novice before their first LSE by ARFI (presentation of the device followed by one LSE). Then, for each patient, LSE by ARFI was performed once by the novice then twice by the expert (Supplementary Table S1 , Supplemental digital content 1, http://docs.google.com/fileview?id = 0B7iOc FJ8m-0yNjRhYTBhY2UtZTQ0MS00OTA2LTg3N-jEtZGJiMz E4NWExOTJh&hl = en). The novice performed LSE (novice ARFI) in the right liver lobe for the first 50 patients (group 1) and in the left lobe for the remaining 51 patients (group 2). The expert, blinded for novice ARFI results, performed a first LSE in the right liver lobe (rARFI) and a second in the left lobe (lARFI). At the end of their LSEs, the expert and the novice recorded the thickness between the liver surface and the skin along the ARFI measurement site.
Definitions
Ten valid measurements were required for each ARFI examination, without exceeding a total of 20 measurements (valid plus invalid). Thus, LSE by ARFI was considered as 'incomplete' when it failed to reach 10 valid measurements after the 20th measurement. The ARFI success rate (%) was calculated as the ratio: number of valid measurements/total number of measurements. The 'ARFI result', expressed as the shear wave speed (m/s), corresponded to the median value of all the valid measurements performed within the examination. The ARFI interquartile range (IQR) reflected the dispersion of the valid measurements performed within the examination; it was calculated as 3rd quartile-1st quartile. When necessary, ARFI IQR was expressed as the ARFI IQR ratio: ARFI IQR/ARFI result. Whole median value of ARFI (wARFI result) corresponded to the median value of all the ARFI measurements recorded by the expert in both the left (lARFI) and right (rARFI) liver lobes.
Liver stiffness evaluation by Fibroscan LSE by Fibroscan was performed as recommended by the manufacturer [4] in the right liver lobe by an experienced operator (more than 2600 LSEs performed before the study) blinded for patient data and ARFI results. As for ARFI, LSE by Fibroscan was stopped when 10 valid measurements were recorded without exceeding a maximum of 20 measurements. Fibroscan results (kPa) were expressed as the median and the IQR of all valid measurements performed, both indexes being directly calculated by the device [4] . Owing to its logarithmic distribution in our study population, Fibroscan results were expressed as log 10 kPa when necessary. LSE by Fibroscan was considered as 'acceptable' when the Fibroscan IQR ratio (i.e. Fibroscan IQR/Fibroscan result) was less than 0.21 [14] .
Fibrosis blood tests
The following blood tests were calculated according to published formulas or patents: Fibrotest [15] , Hepascore [16] , and FibroMeter where cause-specific scores were used [17] [18] [19] . As several studies have shown that these fibrosis blood tests are well correlated with histological fibrosis stages [20, 21] , we used them as independent reference for liver fibrosis. Area of fibrosis (%) was estimated by other cause-specific scores of FibroMeter [17] .
Statistical analysis
Quantitative variables were expressed as the mean ± standard deviation and qualitative variables as a percentage. The Pearson correlation coefficient (Rp) was used to estimate correlation between quantitative variables.
Reproducibility
Owing to the study design (Supplementary Table S1 , Supplemental digital content 1, http://docs.google.com/ fileview?id = 0B7iOcFJ8m-0yNjRhYTBhY2UtZTQ0MS00OT A2LTg3NjEtZGJiMzE4NWExOTJh&hl = en), interobserver agreement for ARFI results was evaluated in the right liver lobe for the first 50 patients (group 1) and in the left lobe for the remaining 51 patients (group 2). Interobserver and intersite agreements for quantitative variables were evaluated with the intraclass correlation coefficient (Ric) [22] . Ric was interpreted as follows: Ric Z 0.87: excellent, 0.87 > Ric Z 0.71: good, 0.71 > Ric Z 0.50: fair, and Ric less than 0.5: poor agreement [2] . To identify the factors independently associated with interobserver agreement for ARFI results, we performed a multiple linear regression using as dependent variable the relative difference between the ARFI results of the two observers (DARFI). DARFI was calculated as the ratio: absolute value of (novice result-expert result/expert result).
Training effect
To evaluate the training effect of ARFI measurement, the first 50 patients included in the study (i.e. group 1) were divided into five consecutive subgroups of 10 patients (subgroups A to E, Supplementary Table S1, Supplemental digital content 1: http://docs.google.com/fileview?id = 0B7iOcFJ8m-0yNjRhYTBhY2UtZTQ0MS00OTA2LTg3NjEtZ GJiMzE4NWExOTJh&hl = en). Interobserver agreement between the expert and novice ARFI results was evaluated in each subgroup, as described earlier [5] .
Diagnostic accuracy
The diagnosis of significant fibrosis was established by using fibrosis blood tests. We applied previously published diagnostic cutoffs (0.50 for FibroMeter [17] , 0.49 for Fibrotest [21] , and 0.50 for Hepascore [16] ) to establish a binary diagnosis of no/mild or significant fibrosis with each fibrosis blood test. The diagnosis appearing most frequently among the blood tests was kept as the final diagnosis. Accuracy of Fibroscan and ARFI for the diagnosis of significant fibrosis was expressed as the area under the receiver operating characteristic curve (AUROC). We performed a perprotocol analysis excluding LSEs with a 0% success rate, and an intention-to-diagnose analysis applying a 'wrong' result to these unsuccessful LSEs. Wrong LSE results were recorded as follows: when the blood tests diagnosed significant fibrosis, the LSE result was the lowest recorded in the study (2.5 kPa for Fibroscan, 0.7 m/s for ARFI); inversely, when the blood tests diagnosed no/mild fibrosis, the LSE result was the highest recorded in the study (75 kPa for Fibroscan, 4.6 m/s for ARFI). Statistical software used was SPSS for Windows, Version 11.5.1 (SPSS Inc., Chicago, Illinois, USA).
Results
Patient characteristics
Patient characteristics are summarized in Table 1 . No patient had hepatitis flare up with aminotransferases higher than 5-fold the upper limit of normal. According to fibrosis blood tests results, 47.5% of patients had significant fibrosis. ARFI results ranged from 0.7 to 4.6 m/s and Fibroscan results from 2.5 to 75 kPa. Fibroscan was acceptable (i.e. with Fibroscan IQR ratio < 0.21) in 71% of patients.
Feasibility of liver stiffness evaluation by acoustic radiation force impulse or Fibroscan Acoustic radiation force impulse versus Fibroscan
We compared the expert rARFI to Fibroscan as both were performed in the right liver lobe. rARFI had a significantly higher LSE success rate compared with Fibroscan (Table 2) . LSE failure (i.e. 0% success rate) occurred in zero patients using rARFI versus six patients using Fibroscan (P = 0.03). Incomplete LSE (i.e. < 10 valid measurements) occurred in four patients using rARFI versus 13 patients using Fibroscan (P = 0.01). Multivariate analysis including age, sex, cause of liver disease, BMI, waist circumference, and skin-liver thickness showed that incomplete LSE by Fibroscan was independently associated with skin-liver thickness only (P = 0.002). Waist circumference was the only independent predictor of incomplete LSE by rARFI (P = 0.02). In the 39 patients having a BMI Z 28 [8] , incomplete LSEs occurred in only three patients using rARFI versus nine patients using Fibroscan (P = 0.03).
Acoustic radiation force impulse: right versus left liver lobe
Comparing expert rARFI and lARFI, rates of LSE failure and incomplete LSE were not significantly different between lobes (Table 2 ). In the subgroup of patients with a BMI Z 28, lARFI had a significantly higher LSE success rate than rARFI.
Acoustic radiation force impulse training
Training study was performed on group 1 in the right liver lobe because of study design. 
Acoustic radiation force impulse results
There was a trend for an increasing expert-novice agreement from subgroups B to E (Table 3) . By multiple linear regression, novice ARFI result was an independent predictor (P < 10 -3
) of expert rARFI result, as expected, but not the patient subgroups. Moreover, a stepwise multivariate analysis including patient subgroup, age, sex, cause of liver disease, BMI, expert rARFI result, expert rARFI IQR ratio, expert rARFI success rate, and liver-skin thickness showed that DARFI was independently associated with expert rARFI IQR ratio (first step, P < 10 -3 ) and expert rARFI success rate (second step, P = 0.01), but not with patient subgroup. Figure 2a depicts the inverse relationship between expert-novice agreement and expert rARFI IQR ratio among the five patient subgroups.
Liver stiffness evaluation success rate
No trend of increasing expert-novice agreement was detected for ARFI success rate among the five consecutive patient subgroups (Table 3) . By multiple linear regression, novice ARFI success rate was an independent predictor (P < 10 -3 ) of expert rARFI success rate, but not the patient subgroup.
Reproducibility of acoustic radiation force impulse results
Interobserver agreement
Owing to the absence of training effect, interobserver agreement for ARFI results was evaluated between the expert and the novice in the whole population. Owing to the study design, reproducibility was evaluated in the right liver lobe for patient group 1 (i.e. expert rARFI vs. novice ARFI) and in the left lobe for group 2 (i.e. expert lARFI vs. novice ARFI).
Interobserver agreement for ARFI results in the whole population was very good (Ric = 0.84, Fig. 3a) . Although ARFI results were not significantly different, interobserver agreement was better in the right liver lobe than in the left lobe, with respective Ric = 0.86 and 0.71 (Table 3) .
Stepwise multivariate analysis including patient group, age, sex, cause of liver disease, BMI, expert ARFI result, expert ARFI IQR ratio, expert ARFI success rate, and liver-skin thickness showed that expert ARFI IQR ratio (P < 10 -3 ) was the only variable independently associated with DARFI. Figure 2b shows precisely the Intraclass correlation coefficient between the expert and the novice. relationship of interobserver agreement for ARFI result as a function of expert ARFI IQR ratio. Interobserver agreement was excellent when the expert ARFI IQR ratio was r 0.30 (Ric = 0.91), thus defining 'acceptable' ARFI, and fair when the ratio was greater than 0.30 (Ric = 0.66).
Intersite agreement
Expert rARFI and lARFI results were compared in the whole population. rARFI results (1.77 ± 0.91 m/s) were significantly different from those of lARFI (1.86 ± 0.62 m/s, P = 0.02 by paired test). Intersite agreement for expert ARFI results was fair (Ric = 0.60, Fig. 3b ). There was one outlier with acceptable ARFI in the right lobe (ARFI success rate 63%, ARFI IQR ratio 0.11) and unacceptable ARFI in the left lobe (ARFI success rate 10%, ARFI IQR ratio 0.33); Ric was 0.72 without this outlier.
Accuracy of acoustic radiation force impulse for liver fibrosis evaluation Acoustic radiation force impulse versus Fibroscan
Expert rARFI results were well correlated with log 10 Fibroscan results (Rp = 0.76, Fig. 3c ), better than did lARFI results (Rp = 0.63, Table 4 ). By stepwise multiple linear regression, expert rARFI result was independently associated with Fibroscan result at the first step (P < 10 -3
, a R 2 = 0.56), FibroMeter at the second step (P < 10 -3 , cumulative a R 2 = 0.62), sex at the third step (P < 10 -3 , cumulative a R 2 = 0.67), and waist circumference at the fourth step (P = 0.011, cumulative a R 2 = 0.69).
Acoustic radiation force impulse and Fibroscan versus fibrosis blood tests
Expert rARFI results were well correlated with fibrosis blood tests ( Table 4) . As expected, correlations between expert rARFI results and fibrosis blood tests increased in acceptable rARFI (i.e. with an expert rARFI IQR ratio r 0.30, Table 4 ). Correlations between LSE results and fibrosis blood tests were higher with Fibroscan than with ARFI (Table 4) . By stepwise multiple linear regression, each blood test was linked to Fibroscan at the first step (Supplementary Table S2 , Supplemental digital content 2, http://docs.google.com/fileview?id = 0B7iOcFJ8m -0yNjRhYTBhY2 UtZTQ0MS00OTA2LTg3NjEtZGJiMzE4N WExOTJh&hl = en). However, multivariate analysis using area of fibrosis as dependent variable identified rARFI at the first step and Fibroscan at the second step as independent predictors (Supplementary Table S2 , Supplemental digital content 2, http://docs.google.com/ fileview?id = 0B7iOcFJ8m-0yNjRhYTBhY2UtZTQ0MS00OT A2LTg3NjEtZGJiMzE4NWExOTJh&hl = en). In the subgroup of patients with acceptable rARFI, rARFI was the only independent predictor of the area of fibrosis.
Diagnostic accuracy for significant fibrosis wARFI had a slightly higher AUROC than rARFI for the diagnosis of significant fibrosis (Table 5 ). In the perprotocol analysis, Fibroscan had a significantly higher AUROC than ARFI (Table 5) , but not in patients with acceptable LSEs (i.e. with ARFI IQR ratio r 0.30 or Fibroscan IQR ratio < 0.21) where wARFI AUROC was 0.876 ± 0.057 and Fibroscan AUROC was 0.912 ± 0.034 (P = 0.59 by unpaired test). Finally, in the intention-todiagnose analysis, AUROCs of Fibroscan, wARFI, and rARFI were not significantly different (Table 5) .
Discussion
This study evaluates several characteristics of ARFI, a new liver stiffness measurement technology.
Methodological aspects
ARFI has been recently evaluated in one study including 86 patients with chronic viral hepatitis [23] . In this study, The perprotocol analysis excluded LSEs with a 0% success rate, the intention-todiagnose (ITD) analysis included them, but as a 'wrong' result. ARFI, acoustic radiation force impulse; AUROC, area under the receiver operating characteristic curve; lARFI, expert ARFI performed in the left liver lobe; LSE, liver stiffness evaluation; rARFI, expert ARFI performed in the right liver lobe; wARFI, whole median value of ARFI (all valid measurements from both expert rARFI and lARFI). ARFI and Fibroscan accuracies for the noninvasive diagnosis of liver fibrosis were not significantly different and interobserver reproducibility of both elastometries were very good. However, the statistical analysis was performed in a perprotocol basis after exclusion of patients with LSE failure. Moreover, interobserver reproducibility was evaluated after conversion of LSE results in Metavir fibrosis stages by applying diagnostic cutoffs calculated in the studied population, and not between ARFI results themselves. The drawback of this conversion has already been described with Fibroscan [9] .
On account of sampling bias and interobserver variations, it is now well established that liver biopsy is the 'best' standard but not the 'gold' standard for liver fibrosis evaluation [24] . Moreover, several studies have shown that fibrosis blood tests are well correlated with fibrosis stages as determined by liver biopsy [20, 21] and may have a better prognostic value than liver biopsy [25] . In our perprotocol analysis, AUROC of Fibroscan for the diagnosis of significant fibrosis established by fibrosis blood tests is similar to those published earlier in studies using liver biopsy as reference [6, 7] . Moreover, AUROC of ARFI in our study was close to the one recently reported [23] . These results suggest the use of fibrosis blood tests as independent reference for the diagnosis of significant fibrosis. Finally, we circumvented the limitations of the reference for liver staging by performing an analysis using area of fibrosis as reference [17] .
Elastography result: speed or stiffness?
Both ARFI and Fibroscan are devoted for the measurement of the speed of a shear wave in the liver. ARFI results are thus expressed as m/s. Fibroscan manufacturer has developed an estimation of the liver stiffness derived from the speed of the shear wave by calculating the Young's modulus expressed as: E = 3rV s 2 where r is the mass density and V s is the shear wave velocity [13] . This calculation is automatically done by the Fibroscan device which then gives a result expressed in kPa. However, such calculation could introduce an error because the mass density r of the liver is considered as a constant when in reality it is different between normal, congestive, fatty, and fibrous livers. Finally, ARFI result seems more relevant because it corresponds to a direct measure of a physical phenomenon whereas Fibroscan result corresponds to a calculated and thus indirect measure.
Feasibility of liver stiffness evaluation Right liver lobe
As Fibroscan success rate increases with operator experience [26] , conditions of LSE by Fibroscan in our study were very good with a highly experienced operator. A major limitation of Fibroscan is the rate of LSE failure, ranging form 2 to 10% [4] . Earlier studies have shown that BMI was the main factor associated with Fibroscan failure [8] and Fibroscan success rate [26] . The Fibroscan generates the shear wave by an external mechanical impulse on the skin. The shear wave has to go through the subcutaneous tissue before reaching the region of interest (Fig. 1a) . In obese patients, the subcutaneous tissue is thick and thus constitutes a barrier that prevents the spread of the shear wave towards the region of interest, leading to failure of stiffness measurement by Fibroscan. In this setting, the skin-liver thickness was the only variable independently linked to incomplete Fibroscan (i.e. < 10 valid measurements) in our study. ARFI circumvents this limitation by generating the shear wave directly in the tissue of interest (Fig. 1b) . Our results show that ARFI provides a significantly higher success rate than Fibroscan in the right liver lobe. Rates of LSE failure or incomplete LSE were also significantly lower with ARFI, even in patients with a BMI Z 28. Finally, as for Fibroscan, LSE by ARFI takes only a few minutes.
To increase Fibroscan feasibility, the manufacturer has developed a specific probe for LSE in obese patients. In a preliminary study including 100 patients with a BMI Z 30, this specific probe significantly decreased the rate of Fibroscan failure from 28 to 12% and the rate of incomplete Fibroscan from 55 to 33% [27] . However, this probe represents a costly supplementary material whereas rARFI provided high feasibility in all patients with a unique probe.
Left liver lobe
It is not possible to perform LSE by Fibroscan in the left liver lobe. By contrast, LSE can be performed in both liver lobes with a high feasibility using ARFI. Indeed, ARFI success rate and the rates of ARFI failure or incomplete ARFI were not significantly different between the two liver lobes.
Ascites
Ascites is a limitation for Fibroscan feasibility [13] . However, the high-energy ultrasound pulses generated by the ARFI probe can go through liquid environments, contrary to the elastic shear wave generated by the mechanical impulse of the Fibroscan transducer. In clinical practice, we routinely performed ARFI in patients with ascites that does not seem to be a limitation of this technique.
Sample bias
Fibroscan measures liver stiffness in a volume that approximates a cylinder, 1 cm wide and 4 cm long. This volume is at least 100 times bigger than that taken by liver biopsy, thus reducing sampling bias. Although ARFI measures liver stiffness in a smaller volume (0.5 Â 1 cm) than Fibroscan, it can do so anywhere in the liver with a high success rate, even in the left lobe; this may result in even greater reductions of sampling bias.
Finally, the ability of ARFI to perform LSE in both liver lobes, even in obese patients, should give it an edge in the current context of increasing obesity and nonalcoholic Liver stiffness evaluation by ARFI Boursier et al. 1081 fatty liver disease in numerous countries. ARFI is thus positioned as a very interesting device for liver stiffness measurement.
Reproducibility of liver stiffness evaluation Interobserver reproducibility
Earlier studies have shown that interobserver reproducibility of Fibroscan results was globally excellent [9, 28] . However, interobserver agreement for Fibroscan results is influenced by several factors and decreased not only in patients with low liver stiffness values, but also in patients with high Fibroscan IQR ratio, high BMI, or LSE measurement in nonrecommended sites [9] . Thus, the reproducibility of Fibroscan results is primarily dependent on patient characteristics on which the operator has no influence. For example, LSE by Fibroscan may be performed in good conditions -that is, in a recommended site and with a low IQR ratio -but reproducibility will remain poor for low Fibroscan results [9] . Our study shows that the reproducibility of ARFI results was dependent only on the ARFI IQR ratio. Interobserver agreement progressively increased as the ARFI IQR ratio decreased, with an excellent reproducibility for ratios r 0.30 defining 'acceptable' ARFI. As it depends only on examination conditions, reproducibility of ARFI results could tend to be very good in all patients: in cases comprising an IQR ratio greater than 0.30, the operator could immediately perform another examination to try to obtain an acceptable ARFI, optionally by changing the site.
Interliver lobe reproducibility
Reproducibility of ARFI results between the two liver lobes was fair in our study (Ric = 0.60). However, there was an outlier with highly discrepant ARFI results because of an unacceptable ARFI in the left lobe: only two valid measurements and IQR ratio = 33%. When this outlier was excluded, intersite agreement became good (Ric = 0.72).
Training
As for LSE by Fibroscan [5] , LSE by ARFI needs no training period. The apparent increase in expert-novice agreement for ARFI results from patient subgroups B to E was attributed to a decrease in ARFI IQR ratio (Fig. 2a) . In contrast to Fibroscan [5] , the ARFI success rate was free of training effect.
Accuracy of liver stiffness evaluation Right liver lobe rARFI results were well correlated with Fibroscan and fibrosis blood test results, especially in acceptable rARFI. These results underline the interest of ARFI for the noninvasive diagnosis of liver fibrosis. However, Fibroscan results correlated slightly better than rARFI results with fibrosis blood tests, and Fibroscan provided a significantly higher AUROC than rARFI in the perprotocol analysis. Is Fibroscan better than ARFI for liver fibrosis evaluation? Owing to a 0% failure rate, the rARFI AUROC became not significantly different from the Fibroscan AUROC in the intention-to-diagnose analysis. Moreover, acceptable rARFI was the only independent predictor of area of fibrosis. These results suggest that ARFI is of great interest for the noninvasive diagnosis and quantification of liver fibrosis. The comparison between ARFI and Fibroscan should be cautiously interpreted as data were not provided by the same study.
Significance of liver stiffness evaluation in the left liver lobe
Despite its high feasibility, lARFI provided the lowest AUROC for the diagnosis of significant fibrosis. However, we calculated the median value of all ARFI measurements performed by the expert in both liver lobes: wARFI provided a slightly higher AUROC than rARFI for the diagnosis of significant fibrosis, and a higher AUROC than lARFI (significant difference in the whole population). Finally, by considering only acceptable LSEs -that is, with LSE IQR ratio r 0.30 for wARFI or less than 0.21 for Fibroscan [14] -wARFI and Fibroscan had similar AUROCs in the perprotocol analysis. This suggests that it might be more relevant to perform LSE in the two liver lobes, which is not possible with Fibroscan, rather than in a single site, to reduce sample bias.
Access to liver stiffness evaluation
Currently, patients with chronic liver diseases have limited access to LSE because Fibroscan is a costly device available only in a few specialized centers. As an add-on module for a standard ultrasound imaging device, ARFI is sold by the constructor at a much lower cost than Fibroscan (Table 6 ). Thus, many centers might be interested in acquiring this device to improve patient access to LSE. Chronic liver diseases are often clinically silent and thus very difficult to screen in the general population. One might suppose that the screening of silent chronic liver diseases may be improved by the systematic use of LSE by ARFI after each abdominal ultrasound, irrespectively of the initial examination indication.
Global comparison of acoustic radiation force impulse and Fibroscan
Our intention-to-diagnose analysis shows that ARFI and Fibroscan diagnostic accuracies for significant fibrosis are not significantly different. However, ARFI circumvents several limitations of LSE by Fibroscan, that is, feasibility and reproducibility. Finally, the comparison of general characteristics of both elastometry devices suggests that ARFI is potentially noteworthy for the noninvasive diagnosis of liver fibrosis, and has more advantages than inconveniences compared with Fibroscan (Table 6 ).
In conclusion, ARFI is a new technology for LSE offering better feasibility than Fibroscan. ARFI needs no training period and provides reproducible results, especially when the ARFI IQR ratio is r 0.30. In an intention-to-diagnose basis, ARFI and Fibroscan accuracies are not significantly different. These elements show that ARFI is noteworthy for the noninvasive diagnosis and quantification of liver fibrosis, especially when considering its easy access.
